Navigation Links
Matthew Sarad to Reverse Aging and Cure Cancer
Date:9/11/2009

ases, such as macular degeneration, arteriosclerosis, osteoporosis, and other degenerative diseases that might be reversed by restoring telomere length.

According to Mr. Sarad, "This experiment is incredibly important. I think we now have a mixture of nanotechnology based gene therapy products that can result in what might be called significant 'organismal rejuvenation'. We have seen regeneration of human tissues in the laboratory. How far this technology can ultimately go is hard to say, but I am optimistic that this is the first step in what will be referred to historically as the moment the age-barrier was broken."

This research may also change the way that cancer is treated in the future. For example, Mr. Sarad's company licensed and improved a protein based anti-cancer therapeutic noted in studies by the University of Nebraska Medical Center to be non-toxic and to cause long-term remission in 80% of all cancer, including difficult to treat neuronal cancer. The Corporation was working on increasing the remission rate further by delivering other tumor suppressor proteins. One or more tumor suppressor genes is corrupted, silenced, or deleted in almost all cancer. This therapeutic drug is being studied today at the country's third largest hospital the Cleveland Clinic in the treatment of cancer and restenosis. The hospital is also studying some of the corporation's tissue regeneration technologies.

Mr. Sarad's career in biotechnology has not been without controversy. In 2008 he was sanctioned by the SEC for alleged securities violations made while taking his company public in 2006. The company, Telomolecular Corp., achieved public status but its shares were later deregistered.

"The mistake I made was being young, inexperienced, and excited about the prospects of our technologies," said Mr. Sarad. "I failed to disclose that our management was inexperienced engineering an IPO and this may have been mislea
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
10. USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration
11. Matthew Lehman of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Switzerland’s MS Tûranor PlanetSolar , the ... record for a transatlantic crossing by a solar electric ... 25, 2013, the solar powered boat sailed 2,867miles (5,310 ... of 5.3 knots before reaching Marigot, St. Martin, in ... first-of-its-kind catamaran completed this year’s passage across the Atlantic ...
(Date:5/19/2013)... The JM Internet Group (web: jm-seo.org), a leader ... that the company's YouTube channel on SEO tips ... YouTube. The company uses YouTube as a way to ... for small businesses with much success. , "I love ... for their SEO strategies", explained Jason McDonald, director of ...
(Date:5/17/2013)... 2013 Topricin Pain Relief and ... been listed among nationally recommended over-the-counter (OTC) health ... by "U.S. News" Health in collaboration with "Pharmacy ... “No. 1 Pharmacists Recommended designation” in the “Topical ... brands, and is the only homeopathic formula to ...
(Date:5/17/2013)... 17, 2013 Dr. Sparano is Professor ... Health at the Albert Einstein College of Medicine and ... Montefiore Medical Center. He is also Associate Director ... leads the Einstein Breast Cancer Working Group, a multidisciplinary ... cancer research. He also serves as Vice Chair of ...
Breaking Biology Technology:MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... May 9 ,Takeda Pharmaceutical Company Limited, "Takeda", (TSE: ... ) today announced the,successful completion of Takeda,s cash ... to acquire all outstanding shares,of Millennium common stock ... period for the tender offer expired at 12:00,midnight, ...
... May 8 Alsius Corporation,(Nasdaq: ALUS ), ... for critically ill patients, today,announced that it will ... quarter results and provide a corporate update. Bill ... host the call beginning at,1:30 p.m. Pacific Time ...
... May 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... 2008 at,8:30 a.m. EDT to discuss the first quarter ... Officer of the Company, will host,the call. Keryx will ... release to be issued prior to the call., ...
Cached Biology Technology:Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 2Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 4Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 5Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008 2Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... China---- Why Tibetan antelope can live at elevations ... collaborative research published in Nature Communications , ... provide evidence that some genetic factors may be ... environments. The data in this work will also ... the biology of other ruminant species. , The ...
(Date:5/17/2013)... climate change may have little impact on many ... recent studies that predict their widespread extinction in ... appear in the journal Global Change Biology ... creature thought to be doomed: http://onlinelibrary.wiley.com/doi/10.1111/gcb.12253/abstract ... forest lizards, will be hard hit by climate ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Climate change may have little impact on tropical lizards 2
... A research team at Worcester Polytechnic Institute (WPI) ... Institutes of Health (NIH) for a project aimed at ... into stem-like cells. If successful, the research could result ... tissue lost to injury, growing new organs, and curing ...
... Erec Stebbins, associate professor at The Rockefeller University, has ... Institutes of Health for a project aimed at exploiting ... into specific cells for therapeutic purposes. The award, which ... by the NIH September 3. The EUREKA program ...
... two Michigan universities have joined technical and clinical ... and computer algorithms to work in the sleep ... that a new approach to analyzing sleep fragmentation ... Joseph W. Burns, a research scientist ...
Cached Biology News:NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 2NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 3NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 4C. Erec Stebbins awarded prestigious EUREKA grant 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Macrophage-stimulating protein receptor...
Biology Products: